CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026

  1. CFO Spotlights
  2. Profiles
  3. Jing-Zhou Chen

Profile

Jing-Zhou Chen

Chief Executive Officer, President, Chief Financial Officer, and Secretary, VitaSpring Biomedical Co. Ltd.

In the seat. First published here October 28, 2026; built from records as of October 28, 2026.

Jing-Zhou Chen has been Chief Executive Officer, President, Chief Financial Officer, and Secretary of VitaSpring Biomedical Co. Ltd. since September 7, 2026, according to the company's filing of September 10, 2026.1

The filing gives Jing-Zhou Chen's previous role as founder and Chief Executive Officer at Dream Born Co., Ltd.1 Jing-Zhou Chen joined from outside VitaSpring Biomedical Co. Ltd., by the record's reading of the filing.1

Another profile on this site carries the same name: Jing-Zhou Chen of Acro Biomedical Co., Ltd.. The filings do not establish that they are the same person, so the records are kept apart.

Seats

The seat in the record

CompanyTitle as filedStandingFilings
VitaSpring Biomedical Co. Ltd. (VSBC)
Services-Commercial Physical & Biological Research
Chief Executive Officer, President, Chief Financial Officer, and SecretaryIn the seat1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. September 7, 2026effective

    VitaSpring Biomedical Co. Ltd. appointed Jing-Zhou Chen as Chief Executive Officer, President, Chief Financial Officer, and Secretary, effective September 7, 2026. Profile of Ssu-Chuan Lai.

    Ssu-Chuan Lai, as the sole director then in office, appointed Jing-Zhou Chen as the Company’s Chief Executive Officer, President, Chief Financial Officer, and Secretary, to serve at the pleasure of the Board and until his successor is duly […]

    [1] Filing by VitaSpring Biomedical Co. Ltd., filed with the SEC on September 10, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Current report filed with the SEC, VitaSpring Biomedical Co. Ltd.. U.S. Securities and Exchange Commission, EDGAR, filed September 10, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Jing-Zhou Chen wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.